Y-mAbs Therapeutics’ (YMAB) “Outperform” Rating Reaffirmed at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a report released on Friday,RTT News reports. They presently have a $23.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 233.82% from the company’s current price.

YMAB has been the subject of several other reports. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Stock Performance

YMAB stock traded down $0.50 during trading on Friday, hitting $6.89. 759,043 shares of the company’s stock traded hands, compared to its average volume of 353,540. Y-mAbs Therapeutics has a 52 week low of $6.84 and a 52 week high of $20.90. The business has a fifty day simple moving average of $10.47 and a 200 day simple moving average of $12.16. The stock has a market capitalization of $308.60 million, a price-to-earnings ratio of -12.76 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the firm earned ($0.18) earnings per share. Research analysts forecast that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its stake in Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after purchasing an additional 2,854 shares during the last quarter. Principal Financial Group Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at about $267,000. Barclays PLC grew its position in shares of Y-mAbs Therapeutics by 433.4% in the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after buying an additional 56,244 shares during the last quarter. Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $210,000. Finally, Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after acquiring an additional 47,846 shares during the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.